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Introduction
============

In lower limb and lower abdominal surgeries, subarachnoid anesthesia is a widely used method for providing regional anesthesia. To provide a prolonged motor and sensory blockade, multiple adjuvants have been utilized, including α-2 agonists, opioids, and 0.5% hyperbaric intrathecal bupivacaine \[[@REF1]\]. Intrathecal, oral, or intravenous administration of an α-2 adrenoreceptor agonist like clonidine is associated with providing an extended duration of spinal anesthesia \[[@REF2],[@REF3]\]. Dexmedetomidine, being free from the side effect of respiratory depression, can be used as an adjuvant in certain clinical settings \[[@REF4],[@REF5]\]. Dexmedetomidine is an α-2-adrenoreceptor agonist and is a more selective drug. It has higher α-2 and α-1 activity as compared to clonidine \[[@REF6]\]. Dexmedetomidine has analgesic, amnestic, and sedative properties \[[@REF7]\]. Dexmedetomidine and clonidine have both been associated with prolongation of sensory as well as a motor blockade in some previous studies \[[@REF8]-[@REF10]\].

Multiple studies support the effectiveness of intravenous as well as intrathecal use of dexmedetomidine to prolong the sensory and motor blockade when administered after inducing spinal anesthesia. In this study, we evaluate the effect of intravenous dexmedetomidine at a dose of 1 µg/kg when administered as a single bolus or an infusion at a dose of 0.5 µg/kg. The efficacy was evaluated based on sensorimotor effects following administration after subarachnoid anesthesia with the help of hyperbaric bupivacaine (12.5 mg). Similarly, the adverse-effect profile was also evaluated between the two different regimens at the same dose of dexmedetomidine. Even though the efficacy of dexmedetomidine has been studied previously in multiple international studies, very little has been reported locally regarding the sensorimotor effect of different regimens of dexmedetomidine.

Materials and methods
=====================

This randomized control trial was performed at the Department of Anesthesia, Nishtar Hospital, Multan, Pakistan, from January 2017 to June 2018. Ethical approval was obtained from the hospital ethics committee. A total of 70 patients, aged 18 to 65 years, enrolled for elective lower limb surgery under subarachnoid anesthesia in the supine position. One or two patients belonging to the American Society of Anesthesiologists (ASA) Physical Status class (Figure [1](#FIG1){ref-type="fig"}) were also included. The sample size was calculated based on the reference study conducted by Kavya et al. \[[@REF11]\]. All the procedures for preparing the mixtures of the drug being administered and administration of the drug to induce subarachnoid block and recording of sensorimotor effects of spinal anesthesia were evaluated by the researcher himself. 
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A non-probability consecutive sampling technique was used to collect the sample. All the patients were randomly enrolled into one of the three groups. The control group received only 2 ml bupivacaine (Group B) in intrathecal space. In the bupivacaine plus dexmedetomidine (single bolus; BDexB) Group, the patients received 2 ml bupivacaine intrathecal and a bolus of 20 ml of normal saline mixed with dexmedetomidine 1 μg/kg in 10 minutes, followed by 20 ml of normal saline for the next 60 minutes. In the BDexI Group, the patients received intrathecal 2 ml bupivacaine plus 20 ml normal saline in 10 minutes, followed by dexmedetomidine infusion at a dose of 1 μg/kg.

After confirmation of cerebrospinal fluid free flow, intrathecal hyperbaric bupivacaine was administered via the L3 to L4 or L4 to L5 interspaces. The time of administration of intrathecal bupivacaine was set as the zero point. A sensory blockade was noted at the level of T10. The motor blockade was also periodically measured until a modified Bromage score of three was achieved. The Ramsay score was used to note the extent of sedation, and adverse effects such as hypotension, bradycardia, and nausea were also measured and recorded. Nausea, vomiting, diarrhea, and pruritus were the adverse effects noted during the study. The statistical analysis was done with the help of IBM SPSS Statistics for Windows, Version 23.0 (IBM, Armonk, NY). The frequency and percentages were calculated for all the qualitative variables, and the mean and standard deviation (SD) were calculated for the quantitative variables. To check and compare the statistical differences between the variables from different groups, Chi-square and ANOVA tests were performed. A probability (p) value of ≤.05 was deemed statistically significant.

Results
=======

All the groups were comparable in age, weight, gender distribution, and ASA status (p: \>.05; Table [1](#TAB1){ref-type="table"}). The time of onset of the sensory and motor blockades was not significantly different between the groups (p: \>.05). The duration of the sensory blockade was longest in the BDexB Group and shortest in the B Group (p: \<.001). The times for complete sensory and motor recovery were shortest in the B Group and longest in the BDexB Group; a statistically significant difference was found (p: \<.001). The Ramsay score was \>2 (i.e., 3 or 4) in five patients from Group B, in 19 patients from Group BDexB, and in 17 patients from the Group BDexI. A statistically significant difference was found (p: \<.001) among all three groups. The rest of the patients in all groups had a Ramsay score of two (Table [2](#TAB2){ref-type="table"}). The incidence of adverse effects such as hypotension, bradycardia, nausea, and peripheral capillary oxygen saturation (SpO2) of \<95% was similar in all groups, and no statistically significant difference was observed (p: \>.05; Table [3](#TAB3){ref-type="table"}).

###### Patient groups

Data are entered as mean ± standard deviation (SD) unless otherwise mentioned.

Group B: group receiving only bupivacaine; Group BDexB: group receiving bupivacaine plus dexmedetomidine as a single bolus; Group BDexI: group receiving intrathecal bupivacaine plus dexmedetomidine as an infusion

ASA I/II: American Society of Anaesthesiologists physical status classification score; SD: standard deviation

  -------------- ------------------ ---------------------- ---------------------- ---------
  Variable       Group B (n = 24)   Group BDexB (n = 23)   Group BDexI (n = 23)   P-value
  Age, years     38.04 (±10.67)     35.39 (±10.79)         38.22 (±10.03)         .594
  Weight, kg     53.75 (±11.69)     62.26 (±15.19)         55.95 (±13.31)         .088
  Male/female    12/12              11/12                  16/7                   .261
  ASA I/ASA II   15/9               17/6                   15/8                   .687
  -------------- ------------------ ---------------------- ---------------------- ---------

###### Patient-group parameters

Data are entered as mean ± standard deviation (SD) unless otherwise mentioned. 

Group B: group receiving only bupivacaine; Group BDexB: group receiving bupivacaine plus dexmedetomidine as a single bolus; Group BDexI: group receiving intrathecal bupivacaine plus dexmedetomidine as a bolus plus infusion 

Min: minutes; SD: standard deviation

  ----------------------------------- ------------------ ---------------------- ---------------------- ---------
  Parameter                           Group B (n = 24)   Group BDexB (n = 23)   Group BDexI (n = 23)   P-value
  Onset of sensory blockade, min      2.3 (±0.2)         2.2 (±0.3)             2.3 (±0.2)             \>.05
  Duration of sensory blockade, min   131.08 (±14.52)    171.43 (±22.89)        163.43 (±16.54)        
  Complete sensory recovery, min      213.02 (±28.45)    301.69 (±32.05)        286.09 (±19.43)        
  Onset of motor blockade, min        2.1 (±0.4)         2.3 (±0.2)             2.2 (±0.3)             \>.05
  Motor recovery, min                 227.71 (±19.02)    332.91 (±16.66)        312.22 (±22.68)        
  Ramsey sedation score (2/3 or 4)    19/5               4/19                   6/17                   
  ----------------------------------- ------------------ ---------------------- ---------------------- ---------

###### Adverse effects observed in patient groups

Group B: group receiving only bupivacaine; Group BDexB: group receiving bupivacaine plus dexmedetomidine as a single bolus; Group BDexI: group receiving intrathecal bupivacaine plus dexmedetomidine as an infusion.

Numbers in parentheses are the percentage figures

SpO2: peripheral capillary oxygen saturation

  ---------------- ------------------ ---------------------- ---------------------- ---------
  Adverse effect   Group B (n = 24)   Group BDexB (n = 23)   Group BDexI (n = 23)   P-value
  Hypotension      6 (25)             2 (8.7)                2 (8.7)                .181
  Bradycardia      2 (8.3)            4 (17.4)               5 (21.7)               .435
  Nausea           1 (4.2)            3 (13)                 2 (8.7)                .554
  SpO2 of \<95%    1 (4.2)            4 (17.4)               4 (17.4)               .292
  ---------------- ------------------ ---------------------- ---------------------- ---------

Discussion
==========

In this study, the effect of dexmedetomidine on subarachnoid anesthesia with intrathecal hyperbaric bupivacaine was evaluated when dexmedetomidine was given as a single bolus or infusion. In either method, the time required for the beginning of a sensory block was similar and comparable to results previously reported in other studies \[[@REF9],[@REF12],[@REF13]\]. However, Harsoor et al. suggested different results and showed that dexmedetomidine was associated with a shorter time required for the onset of the sensory block as compared to the control group \[[@REF5]\]. In this study, it is evident that the mean time taken by the two-segment regression or recovery of sensory block was also prolonged. This is in accordance with some previous studies \[[@REF5],[@REF14]-[@REF16]\]. The beginning of the motor blockade was comparable in all three groups in this study. Another study reported results similar to our study in terms of a comparable time for motor-block onset \[[@REF8]\], while dexmedetomidine was associated with shortening the time necessary for the motor-block onset by a duration of one minute \[[@REF17]\].

In both groups receiving dexmedetomidine, sensory recovery was comparable to the control group. This aligns with the conclusion made by previous studies \[[@REF8],[@REF10]\]. For either the bolus or bolus plus infusion, the motor blockade induced by dexmedetomidine was comparable. Similar results have been shown in some past studies \[[@REF5],[@REF10],[@REF14],[@REF17],[@REF18]\]. In other previous studies, the time taken to return to a modified Bromage scale of one was taken as the duration of the motor blockade \[[@REF12],[@REF15],[@REF19],[@REF20]\]. This study showed that dexmedetomidine did not alter the time required by the motor blockade to return to a modified Bromage scale of zero. Some previous studies have deduced similar results as dexmedetomidine did not prolong the duration of the motor blockade in these studies. The prolongation of the motor blockade seen in this study can be attributed to the fact that we took a modified Bromage scale of zero as the endpoint. In this study, there were three groups: Group B received intravenous normal saline; Group BDexB was administered intravenous dexmedetomidine as a single bolus; Group BDexI was administered dexmedetomidine as an infusion. The post-hoc analysis found no statistically significant difference in the two groups receiving dexmedetomidine.

Only one similar study has been reported previously regarding the effect of dexmedetomidine as a single bolus or as a bolus plus infusion. As in our study, a similar study found no difference between the two groups administered with dexmedetomidine \[[@REF11]\]. Further studies are required to evaluate the difference between single bolus and bolus plus infusion regimens of dexmedetomidine. As far as the sedation was concerned, it was monitored with the help of a six-point Ramsay score. The sedation scores in this study were higher in patients receiving dexmedetomidine, but the reversal of sedation was easy. These findings were also present in other studies where dexmedetomidine was used \[[@REF7]\]. Similarly, oxygen saturation also did not drop significantly in this study and was easily treated with the help of oxygen supplementation. Similar results were found in a previous study where no patient developed desaturation of oxygen with the use of dexmedetomidine \[[@REF21],[@REF22]\].

Our study was not without limitations. We included only those patients who needed lower limb surgery with ASA I and II in our study. More trials are needed on other types of surgeries and additional ASA grades. These studies would provide more clarity regarding the efficacy of dexmedetomidine on intrathecal bupivacaine.

Conclusions
===========

Our study concludes that the intravenous administration of dexmedetomidine as either a bolus or an infusion prolongs the duration of the sensory and motor blockade.
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